CK2α Prodrug Inhibitors With αD-Site Selectivity and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CK2α inhibitors target the highly conserved ATP binding site, leading to poor selectivity and solubility issues, necessitating the development of potent and selective CK2α inhibitors, including prodrug forms that interact with the αD site to inhibit CK2α activity effectively.
Innovation Solution
Development of compounds (Formulae I and II) and their pharmaceutically acceptable salts, hydrates, or solvates, which can bind to the catalytic ATP site of CK2α while interacting with the αD site, enhancing selectivity and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CK2α inhibitors target the highly conserved ATP binding site, then they achieve enzyme inhibition, but they exhibit poor selectivity over other kinases
Solution Approach 1:
The patent applies local quality by designing inhibitors with distinct functional regions: one region targets the ATP binding site for enzyme inhibition, while another region specifically interacts with the αD site of CK2α. This spatial differentiation of binding functions enables both potent inhibition and high selectivity, resolving the contradiction between these two parameters.
2Quantity of substance
If prodrugs are developed to improve solubility, then solubility issues are addressed, but the complexity of the compound structure increases
Solution Approach 1:
The patent uses prodrugs as intermediary compounds that temporarily modify the inhibitor structure to improve solubility properties. These prodrugs contain additional functional groups or moieties that enhance aqueous solubility, and are designed to be converted in vivo to the active inhibitor form, thus resolving the solubility issue without permanently increasing structural complexity.
Data Source
AI summary
Provided are compounds of the Formula II, and salts, hydrates and solvates thereof:wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.